Browsing Tag
NYSE: MRK
3 posts
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
Can Merck rebuild its cardiovascular empire post-Keytruda? A closer look at its next decade of drug growth
With Keytruda’s patent expiry nearing, Merck is betting on enlicitide and sotatercept to build a new cardiovascular empire. Can it succeed?
Merck’s enlicitide shows major LDL-C reduction in Phase 3 trials, raising hopes for first oral PCSK9 approval
Merck’s enlicitide hits key milestones in Phase 3 trials, bringing the first oral PCSK9 inhibitor closer to market. Will this reshape LDL-C treatment?